Thursday, May 17, 2012
GlaxoSmithKline plc and Yale University
researchers have announced a collaboration to develop a platform that
selectively tags disease-associated proteins with an E3 ubiquitin ligase ligand, thus
targeting them to a cell's protein degradation machinery. GSK hopes the
platform could be a cornerstone for a new Discovery Performance Unit at the
pharma, and the partners are aiming to have proof-of-principle results in cell
culture by year end.
K.-J. SciBX 5(20);
doi:10.1038/scibx.2012.514 Published online May 17, 2012
1. Sakamoto, K.M. et al. Proc. Natl.
Acad. Sci. USA 98, 8554-8559 (2001)
2. Buckley, D.L. et al. J. Am. Chem.
Soc. 134, 4465-4468 (2012)
3. Neklesa, T.K. et al. Nat. Chem.
Biol. 7, 538-543 (2011)
California Institute of Technology, Pasadena, Calif.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Yale University, New Haven, Conn.